Larimar Therapeutics, Inc. (LRMR) — 10-Q Filings

10-Q Filings (6)

• Larimar's R&D Surge Drives Q3 Loss to $47.7M Amid Nomlabofusp Push — Nov 5, 2025 Risk: high
  Larimar Therapeutics, Inc. (LRMR) reported a significant increase in net loss for the three and nine months ended September 30, 2025, primarily driven by a subs
• Larimar's R&D Surge Drives 53% Net Loss Increase Amid Clinical Trials — Aug 14, 2025 Risk: high
  Larimar Therapeutics, Inc. (LRMR) reported a significant increase in net loss for the six months ended June 30, 2025, reaching $55.46 million, up from $36.28 mi
• Larimar Therapeutics Files Q1 2025 10-Q — Apr 30, 2025 Risk: medium
  Larimar Therapeutics, Inc. filed a 10-Q for the period ending March 31, 2025. The company, formerly known as Zafgen, Inc., is in the pharmaceutical preparations
• Larimar Therapeutics Files Q3 2024 10-Q — Oct 30, 2024 Risk: medium
  Larimar Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as ZAFGEN, INC., reported research and developme
• Larimar Therapeutics Files Q2 2024 10-Q — Aug 8, 2024 Risk: medium
  Larimar Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business o
• Larimar Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — May 9, 2024 Risk: low
  Larimar Therapeutics, Inc. (LRMR) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Larimar Therapeutics, Inc. filed a 10-Q report for the period end

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX